Altasciences Names Setnik as Chief Scientific Officer
9 August 2019 - - Canada-based contract research organisation Altasciences has named Dr. Beatrice Setnik, Ph.D. to the role of chief scientific officer, supporting our internal and external clients with her expertise in all areas relating to early drug development, the company said.

Setnik has a Ph.D. in Pharmacology and Neuroscience from the University of Toronto and since 2005 has been involved in clinical trials in Canada and the USA.; with Ventana Clinical Research in Canada, King Pharmaceuticals and Pfizer in North Carolina, and since 2014 with Syneos Health (formerly INC Research).

She has extensive experience in the design, conduct, and reporting of trials in a wide range of therapeutic areas, including expertise in the assessment of abuse and dependence potential of CNS-active drugs.

In addition, she is an Adjunct Professor in the Department of Pharmacology and Toxicology at the University of Toronto and regularly participates in FDA meetings and workshops.

Setnik's wealth of knowledge and experience will ensure high-level scientific guidance and input on study designs, protocols, and medical and scientific feasibility for new inquiries for current and prospective clients.

Altasciences is a forward-thinking, mid-size contract research organisation offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept.

For over 25 years, Altasciences has been integrating into clients' projects to help support educated, faster, and more complete early drug development decisions.

Altasciences' full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, programme management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.